quinazolines has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beraldi, E; Bishop, JL; Cordonnier, T; Gleave, ME; Kuruma, H; Nip, KM; Shiota, M; Takeuchi, A; Zoubeidi, A | 1 |
| Guo, Z; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X | 1 |
2 other study(ies) available for quinazolines and mdv 3100
| Article | Year |
|---|---|
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Y-Box-Binding Protein 1 | 2015 |
Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Topics: Animals; Apoptosis; Autophagy; Benzamides; Benzylamines; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Disease Models, Animal; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Models, Biological; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |